ArticleJournal of intensive care2025
Preliminary application of the Sharesource connect data collection and analysis system in the management of continuous renal replacement therapy in the intensive care unit.
Article in Journal of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study investigated the application of software-based data monitoring for quality control (QC) in continuous renal replacement therapy (CRRT) management.
methodsThis single-center pre-post intervention study, conducted in three ICUs of a tertiary hospital in Shanghai, compared outcomes before (Jan-Dec 2023) and after (Jan-Dec 2024) implementing the Sharesource Connect system. Data from 9 Prismaflex CRRT machines were collected retrospectively during 2023 and prospectively on a monthly basis during 2024. Alongside the software, a comprehensive quality improvement program: (1) multidisciplinary team collaboration; (2) data-driven QC; and (3) structured training. Primary outcomes-filter lifespan, downtime percentage, delivered/prescribed dose ratio, ultrafiltration volume, and vascular access alarms-were compared.
resultsA total of 798 filters from 514 patients (2023) and 717 filters from 492 patients (2024) were analyzed. Key quality metrics improved significantly following implementation (2024 vs. 2023): Filter lifespan increased significantly from 20.08 ± 4.12 h to 24.08 ± 4.27 h (P = 0.043), Kaplan-Meier analysis demonstrated improved filter survival (Log-Rank p < 0.001). Cumulative survival increased from 2023 to 2024 at key time points: 12 h (69.1%-87.2%, + 18.1%), 24 h (30.9%-34.6%, + 3.7%), and 36 h (5.6%-13.6%, + 8.0%), with consistent improvements observed. Downtime percentage decreased from 39 to 28% (P = 0.015), reducing non-effective treatment time by 11 percentage points. The delivered/prescribed dose ratio increased from 82 to 86% (P = 0.046). The mean delivered dose was 35.67 ± 4.01 mL/kg/h (prescribed: 41.33 ± 4.5 mL/kg/h). Ultrafiltration volume remained stable (3.13 ± 0.37 vs. 3.52 ± 0.44 L/treatment day, P = 0.058). There was no significant difference in vascular access alarms (3.39 ± 1.44 vs. 2.93 ± 0.73 events/day, P = 0.392).
conclusionThe Sharesource Connect system could be used for the monitoring, collection, and analysis of CRRT data to assist in the QC management related to CRRT, so as to provide a software basis for further multi-center studies or random control trials on the intelligent management of critical patients undergoing CRRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.